DIAGNOSTIC SOLUBLE URINE TEST FOR INTERSTITIAL CYSTITIS

Information

  • Research Project
  • 2646913
  • ApplicationId
    2646913
  • Core Project Number
    R43DK053150
  • Full Project Number
    1R43DK053150-01A1
  • Serial Number
    53150
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/1/1998 - 26 years ago
  • Project End Date
    7/31/1999 - 25 years ago
  • Program Officer Name
    NYBERG, LEROY M.
  • Budget Start Date
    8/1/1998 - 26 years ago
  • Budget End Date
    7/31/1999 - 25 years ago
  • Fiscal Year
    1998
  • Support Year
    1
  • Suffix
    A1
  • Award Notice Date
    7/31/1998 - 26 years ago
Organizations

DIAGNOSTIC SOLUBLE URINE TEST FOR INTERSTITIAL CYSTITIS

DESCRIPTION: (Adapted from the investigator's abstract) Interstitial cystitis (IC), or non-bacterial cystitis, is a vaguely defined chronic inflammatory bladder uroepithelial syndrome responsible for a debilitated lifestyle in up to 450,000 patients in the U.S., 90% of which are women. Urologic diagnosis of IC currently requires invasive procedures such as cystoscopy or a direct bladder biopsy for evidence of either glomerulations or Hunner's ulcers. There exists no clinical consensus model for IC etiology, which is reflected by the critical lack of a useful laboratory test for definitive diagnosis and therapeutic monitoring response. In this Phase I study, it is proposed to develop, conducive to a commercial service laboratory environment, a reproducible semi-automated ultrasensitive ELISA immunoassay for soluble urine specimens and evaluate its diagnostic validity for IC using urine samples from a defined clinical population. Assay basis will involve quantitation of antiproliferative factor immunoreactivity associated with a soluble low molecular weight urine putative antiproliferative factor as applied to in vitro-cultured cells. The studied populations will entail IC patients defined by NIDDK criteria, as well as diagnosed non-IC urine specimens from gynecological and urologic patients whose symptoms mimic IC. Assay results will be statistically analyzed to yield sensitivity, specificity, positive predictive values and negative predictive values for these defined patient populations. PROPOSED COMMERCIAL APPLICATION: NOT AVAILABLE

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG2
  • Study Section Name
  • Organization Name
    UROCOR, INC.
  • Organization Department
  • Organization DUNS
  • Organization City
    OKLAHOMA CITY
  • Organization State
    OK
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    73104
  • Organization District
    UNITED STATES